Model-Based ATG Dosing Successfully Accelerates CD4+ Reconstitution in CD34+ Selected Allogeneic HCT
Introduction: Balancing GVHD Prevention and Immune Reconstitution
The landscape of allogeneic hematopoietic cell transplantation (HCT) has been defined by a precarious balance between preventing graft-versus-host disease (GVHD) and ensuring rapid immune recovery. Ex vivo CD34+ selection, a process that physically removes T-cells from the donor graft, has emerged as a powerful technique to minimize the risk of chronic GVHD without the need for prolonged immunosuppression. However, this method has historically been hampered by delayed immune reconstitution (IR), specifically the slow recovery of CD4+ T-cells, which increases the patient’s vulnerability to opportunistic infections and non-relapse mortality (NRM).
The Role of Antithymocyte Globulin
Sign in free to continue reading
Create or use your MedXY account to unlock the complete article.
This article was created using several editorial tools, including AI, as part of the process. Human editors reviewed this content before publication.